Abe Yōandō Pharmaceutical Selected as XPRIZE Healthspan Finalist

Abe Yōandō Pharmaceutical's Achievement in Health Science

Abe Yōandō Pharmaceutical Co., Ltd., headquartered in Adachi, Tokyo, has achieved remarkable recognition by being selected as a finalist for the globally renowned XPRIZE Healthspan competition. This highly esteemed event, aimed at extending human healthspan, is organized by the XPRIZE Foundation, known for hosting prominent competitions supported by high-profile investors, including Elon Musk. The company received an award for excellence and will be announced as one of the 20 finalists on August 11, 2026, Eastern Time.

Understanding XPRIZE Healthspan

The XPRIZE Healthspan competition is a large-scale global scientific initiative focused on enhancing the human healthspan. It has attracted 799 teams from 58 countries, all competing for a total prize pool exceeding 15 billion yen. The competition encourages researchers to develop functional solutions that aim to rejuvenate muscle, cognitive, and immune functions by more than ten years. Experts from the fields of aging biology, geriatric medicine, immunology, clinical trials, and longevity medicine serve as judges.

Significance of Reaching the Finals

The selection of Abe Yōandō for the finals signifies that the clinical trial data submitted by the company met the global standards of evaluation, meriting advancement to the final stage. As research in longevity accelerates worldwide, it is a proud moment as a Japanese company stands on the global stage.

Foundations of Clinical Trial Data

The foundation for advancing to the finals is based on clinical trial results submitted in April 2026. The study involved healthy men and women aged 47 to 65, divided into two groups: one receiving an intervention containing the active ingredient and the other a placebo. Over 42 days, participants consumed a drink containing NMN (Nicotinamide Mononucleotide) and herbal components, evaluating muscle, cognitive, and immune functions.

- Increased physical activity and improved memory processing speed were observed.
- A decrease in the inflammation marker IL-6 and an increase in IL-10, which generally declines with age.
- Functional age analysis based on comprehensive aging data indicated rejuvenation by approximately 2.8 years in the intervention group.
- Biological age, measured through DNA methylation, showed an average rejuvenation of about 4 years, with some participants demonstrating improvements of up to 13 years.

These results exemplify measurable improvements in both functional and biological health within just 42 days. It is important to note that these results pertain to a clinical study conducted by the company and do not indicate efficacy for pharmaceutical approval.

Future Developments Towards 2030

As the final stage approaches, Abe Yōandō Pharmaceutical plans to execute a more extensive clinical trial with 100 participants over one year, seeking to validate rejuvenation of more than ten years. The ultimate results of the competition will be announced at an award ceremony scheduled for 2030 in the United States.

Comments from President Tomonari Abe

Tomonari Abe, the President of Abe Yōandō Pharmaceutical, emphasized the significance of this achievement: “To be recognized on this global stage through our advancements built on nearly 300 years of experience and modern science is a huge encouragement. It reinforces our commitment to accurately measuring efficacy. Being selected as a finalist is not the end but a starting point towards genuine healthspan extension. We are dedicated to demonstrating a rejuvenation of over ten years in the final round with our one-of-a-kind formulation.”

About Abe Yōandō Pharmaceutical

Founded in 1731, Abe Yōandō Pharmaceutical has blended the wisdom of Eastern medicine with insights from Western science to advance health longevity. As a pioneer in Japan's field of longevity research, the company is committed to ongoing development within this essential domain.

Company Information:

- Head Office/Showroom: 1-5-4 Yanagihara, Adachi-ku, Tokyo 120-0022, YAK Kitasenju Building
- Ginza Office: 6-3-12 Ginza, Chuo-ku, Tokyo 104-0061, Sukiya Building 6F
- Established: 1731 / Incorporated: December 1984
- President: Tomonari Abe